Pharmacokinetics and Central Haemodynamic Effects of Doxorubicin and 4′Epi-Doxorubicin in the Pig

References

• Carter SK. Adriamycin—a review. J Natl Cancer Inst 1975; 55: 1265–74
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Brambilla C., Rossi A., . Epirubicin in advanced breast cancer. the experience of the Milan Cancer Institute. Advances in anthracycline chemotherapy, G Bonadonna, et al. Masson Italia Editori, Epirubicin. Milan 1984; 63–70
   Google Scholar
• Cersosimo R. J, KiHong W. Epirubicin: Review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425–39
   PubMed Web of Science ®Google Scholar
• Jain K. K, Casper E. S, Geller N. L, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818–26
   PubMed Web of Science ®Google Scholar
• Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62: 955–61
   PubMedGoogle Scholar
• Lenaz L., Page J. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111–20
   PubMed Web of Science ®Google Scholar
• Von Hoff D. D, Rozencweig M., Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982; 9: 23–33
   PubMed Web of Science ®Google Scholar
• Minow R. A, Benjamin R. S, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy—an overview with determination of risk factors. Cancer Chemother Rep 1975; 6: 195–201
   Google Scholar
• Young C. W, Casper E. S, Geller NL. Clinical and cineangiographic comparison of the cardiotoxic effects of epirubicin and doxorubicin. International Symposium of Advances in Anthracycline Chemotherapy. MilanItaly 1984; 19, Abstract
   Google Scholar
• Ganz W., Tamura K., Marcus H. S, Donoso R., Yoshida S., Swan HJ. Measurement of coronary sinus blood flow by continuous thennodilution in man. Circulation 1971; 44: 181–95
   PubMed Web of Science ®Google Scholar
• Levett J. M, Reploge RL. Thermodilution cardiac output: a critical analysis and review of the literature. J Surg Res 1979; 27: 392–404
   PubMed Web of Science ®Google Scholar
• Eksborg S., Ehrsson H., Andersson I. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr 1979; 164: 479–86
   PubMed Web of Science ®Google Scholar
• Eksborg S., Ehrsson H. Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides. J Pharmac Biomed Anal 1984; 2: 297–303
   PubMedGoogle Scholar
• Thornhill D. P, Schwerzel E. Striterfit, a least-squares pharmacokinetic curve-fitting package using a programmable calculator. J Pharm Sci 1985; 74: 545–9
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. G, Riegelman S., Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 1974; 2: 123–48
   PubMedGoogle Scholar
• Atkins GL. Tests for the goodness of fit of models. Biochem Soc Trans 1976; 4: 357–61
   PubMedGoogle Scholar
• Kantrowitz N. E, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195–200
   PubMed Web of Science ®Google Scholar
• Balk MW. Emerging models in the USA: Swine, wood-chucks, and the hairless guinea pig. Prog Clin Biol Res 1987; 229: 311–26
   PubMedGoogle Scholar
• Herman E. H, Ferrans JF. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 1983; 49: 69–77
   PubMed Web of Science ®Google Scholar
• Bristow M. R, Sageman W. S, Scott R. H, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980; 2: 487–515
   PubMed Web of Science ®Google Scholar
• Ditchey R. V, Le Winter M. M, Higgins CB. Acute effects of doxorubicin (adriamycin) on left ventricular function in dogs. Int J Cardiol 1984; 6: 341–50
   PubMedGoogle Scholar
• Eksborg S., Andersson M., Domellof L., Lonroth U. A pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intra-arterial liver administration. Med Oncol Tumor Pharmacother 1986; 3: 105–10
   PubMedGoogle Scholar
• Eksborg S., Stendahl U., Lonroth U. A comparative pharma-cokinetic study of adriamycin and 4′epi-adriamycin after their simultaneous intravenous administration. Eur J Clin Pharmacol 1986; 30: 629–31
   PubMed Web of Science ®Google Scholar
• Unverferth D. V, Magorien R. D, Unverferth B. P, Talley R. L, Balcerzak S. P, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 1981; 65: 1093–7
   PubMedGoogle Scholar